Mirvie, founded in 2018, is a biotech company focused on revolutionizing pregnancy health through early detection of complications. They aim to detect complications months before they occur, through leverage of a proprietary RNA platform that analyzes tens of thousands of RNA messages in a simple blood test. Early detection allows for proactive intervention and improved pregnancy outcomes for both mothers and babies. This platform will help reveal the underlying mechanisms behind pregnancy health and is capable of predicting pre-eclampsia and preterm birth months in advance. Also, the non-invasiveness of a blood test eliminates the risks associated with traditional diagnostic procedures. Their platform is designed to be personalized for each pregnancy.

Mirvie

Founded: 2019
Location: South SF, CA
Employee range: 11 - 50
Funding: $60M May 2022; $90M total as of May 2022
Investors: Decheng Capital. BlackRock, Foresite Capital, General Catalyst, GV, Khosla Ventures, Mayfield

Short description:

Drug notes:

Long description:

Jobs: